01.2023 Emergency management of severe hyponatremia (full o).
01.2023 Emergency management of severe hyponatremia (full o).
03.2023 hypercalcemia (full o).
04.2023JAMA: Hyperthyroidism (full O)**
05.2023 Long-term and sequential osteoporosis** (full o).
06.Subacute thyroiditis in 2022: mechanisms and progression (all O).
07.2023 Normal serum calcium with elevated PTH: diagnosis and treatment (all O).
08.Clinical Review l 2023 Gynecomastia (All O).
09.2023 Polycystic Ovary Syndrome (PCOS) Assessment and **International Evidence-Based Guidelines Recommendation (All O).
10.2022 Emerging methods for hyperthyroidism (full o).
11.2023 Thyroglobulin and Thyroglobulin Antibodies: Clinical and Laboratory Expert Consensus Update (All O)**
12.2023 Pituitary Society International Consensus: Diagnosis and Core Recommendation (O) for Prolactinomas
13.2023 ESC Guidelines: Reducing Cardiovascular Risk in People With Diabetes - Goals and ** (All O).
14.2023 Lancet DE: Thyrotoxicosis Hyperthyroidism (full text, o)**
15.2023ETA: Guidelines for the management of thyroid nodules (full text O).
16.2023JAMA: Cushing's syndrome (all O).
17.2022 Chinese Guidelines for Hyperthyroidism - 131 Iodine** of GD (CK Essentials Annotated Edition).
18.2023 ESE Clinical Practice Guidelines: Adrenal Accident Tumor Management - Core Recommendations.
19.2022 Physiology of Insulin Secretion (Full Text).
20.2023 Weight Loss Drugs: Progress and Challenges (Professional Edition, Full M).
21.2023lancet Thyroid Cancer.
22.Management of Thyroid Eye Disease (TED Thyroid Eye Disease) 2022 (Chart Version) l ATA &ETA Joint Consensus Statement.
23.2023 Laboratory Test Interference Endocrinologists Should Be Aware of: More Than Hook Effect and Heterophile Antibodies (Total).
24.2023 U.S. AACE Consensus Statement: Integrated Type 2 Diabetes Management Process - Update (Full Text, Collector's Edition).
25.2023 JAMA Review: Diagnosis and Treatment of Pituitary Adenomas (Full Text, Collector's Edition).
26.2020 ESE Clinical Practice Guidelines: Endocrine Examination in Obese Patients (Full).
27.Gout 2022: Diagnosis and Progression (Full Version).
28.2022 Primary hyperaldosteronism - revisiting connotation and extension (full text).
29.2023 Vitamin D: Current Controversy.
30.2023**Hypercalcemia of malignant tumors**: ES clinical practice guidelines (full text).
31.2022 Advances in Emerging Hypoglycemic Drugs (Full).
32.2023 Will primary aldehyde become a pure internal medical disease?Focus on the specific aldosterone synthase inhibitor baxdrostat
33.2022WHO adrenocortical tumor classification guidelines (full).
34.2022 Fragile Diabetes.
35.2023 Monogenic Diabetes (All).
36.2022 Lancet: Type 2 Diabetes (Full Text).
37.2023 Cushing's disease (pituitary ACTH tumor) (full).
38.2019 Sarcopenia: European Consensus on Revised Definitions and Diagnosis (Full).
39.2023 Subclinical Cushing Syndrome Guidance Recommendations (CK Essence Interpretation Version).
40.2023 Differentiation of polycystic ovary syndrome and adrenal gland disease (full text).
41.2022 European ESE: Guidelines for endocrine-related adverse reactions of immune checkpoint inhibitors (full).
42.2022 Glucocorticoid-Induced Hyperglycemia and Diabetes Mellitus (Professional Edition).
43.2022 Primary hyperaldosteronism: diagnosis and ** (full).